The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories ยท page 19 of 23

Stories

  1. Eli Lilly and Company, Boehringer Ingelheim, and IgA Nephropathy: the issue of September 28, 2026

    The week of September 28 to October 4, 2026: 29 briefs, 3 stories, led by Eli Lilly and Company, Boehringer Ingelheim, and IgA Nephropathy.

  2. NOPARK trial reports nicotinamide riboside does not improve clinical outcomes in Parkinson disease

    The authors reported that among 393 participants, the total MDS-UPDRS score increased by 2.45 points with nicotinamide riboside and decreased by 0.27 points with placebo, yielding an adjusted mean difference of 2.72 points favoring placebo. Non-motor symptom burden worsened more with nicotinamide riboside, with an adjusted mean difference of 4.22 points.

  3. RINGSIDE Phase II Study of Varegacestat for Desmoid Tumors

    The authors reported that 42 participants were randomized to three dose regimens of varegacestat, with median tumor volume reductions at week 16 of -51.91%, -15.25% and -9.50% for the 1.2-mg once-daily, 2-mg intermittent and 4-mg intermittent doses, respectively. In the open-label extension, 29 participants received 1.2-mg once-daily and achieved a median best tumor volume change of -85.88% and a confirmed objective response rate of 57.1%.

  4. Lilly releases new exploratory data from TOGETHER-PsO Phase 3b trial

    The company announced exploratory biomarker data from the TOGETHER-PsO Phase 3b study showing broader immune and metabolic changes when Taltz (ixekizumab) and Zepbound (tirzepatide) were used together versus Taltz alone. The analysis reported 482 versus 140 differentially expressed proteins and 467 versus 16 genes at Week 36, with greater reductions in inflammatory immune activity.

  5. BioMarin presents new VOXZOGO data at ASBMR 2026

    BioMarin will present new data from 13 studies, including a randomized, double-blind, placebo-controlled trial on VOXZOGO's effect on foramen magnum and craniocervical junction growth in children with achondroplasia. The company will also share data on the investigational long-acting medicine BMN 333 and on VOXZOGO's potential use in hypochondroplasia, for which it has submitted a supplemental New Drug Application.

  6. Viking Therapeutics registers Phase 3 trial of VK2735 for weight management

    The study, titled SUNRISE 1, is a Phase 3 randomized, double-blind, placebo-controlled trial of VK2735 administered orally for weight management. It plans to enroll 560 participants starting October 15, 2026, with primary completion projected for July 2028.

  7. FrieslandCampina registers Phase 3 trial of infant formula with bio-active ingredients

    The study was first posted on ClinicalTrials.gov on October 9, 2026, and plans to enroll 387 participants with a start date of January 2027. It aims to compare growth, immune parameters, and gut health between infants receiving the investigational formula and those receiving a control formula.

  8. Viking Therapeutics registers Phase 3 trial of VK2735 for weight management in type 2 diabetes

    The study plans to enroll 560 participants and is expected to begin on October 16, 2026. It plans to evaluate oral VK2735 for weight management in adults with type 2 diabetes who are obese or overweight.

  9. Hoffmann-La Roche posts results of Phase 3 IMpower030 atezolizumab trial in resectable NSCLC

    Results for the IMpower030 study were first posted on ClinicalTrials.gov on October 9, 2026. The Phase 3 trial enrolled 453 participants and completed primary data collection on October 1, 2025.

  10. Hoffmann-La Roche posts results of Phase 3 alectinib rollover study

    Results for the study were first posted on ClinicalTrials.gov on October 9, 2026. The completed Phase 3 rollover study enrolled 50 participants and compared alectinib with crizotinib in patients with ALK- or RET-positive cancer.

  11. Sanofi posts results of Phase 3 Itepekimab trial in COPD

    The study, NCT04751487 (AERIFY-2), enrolled 1234 participants and completed in April 2025. It evaluated itepekimab versus placebo on exacerbation rates, pulmonary function, and safety in moderate-to-severe COPD patients.

  12. Sanofi posts results of Phase 3 MenACYW conjugate vaccine study in infants

    Sanofi Pasteur posted results of a Phase 3 study that compared MenACYW conjugate vaccine with Nimenrix in 840 infants on 2026-10-07. The record lists geometric mean titers and seroresponse for serogroups A, C, W and Y.